A research team at Yeungnam University has identified a potential breakthrough in treating the root causes of aging itself, not just its symptoms. Scientists discovered that homoharringtonine, a drug traditionally used to treat blood cancer, can selectively remove senescent cells,damaged cells that accumulate in the body as we age,while leaving healthy cells untouched. In animal studies, this approach simultaneously improved obesity and blood glucose control, suggesting a single treatment could address multiple age-related diseases at once .

What Are Senescent Cells and Why Do They Matter as We Age?

Senescent cells are cells that have stopped dividing but refuse to die. As the human body ages or becomes obese, these dysfunctional cells gradually accumulate in adipose, or fat, tissue. Once there, they trigger chronic inflammation, impair the function of surrounding healthy cells and tissues, and make weight gain more likely while hindering effective blood glucose control . Think of them as cellular zombies: they're not alive in the traditional sense, but they're not dead either, and their presence causes problems for everything around them.

The significance of this discovery lies in its fundamental approach. Rather than treating obesity or diabetes as separate diseases, researchers identified senescent cell accumulation as a shared root cause. By targeting that single mechanism, the team demonstrated the potential to alleviate multiple chronic conditions simultaneously.

How Did Researchers Test Homoharringtonine's Anti-Aging Effects?

The research team, led by Professor Park So-young at Yeungnam University's College of Medicine, conducted animal experiments demonstrating that homoharringtonine could reduce senescent cells in adipose tissue with minimal impact on normal cells. The drug, derived from the Cephalotaxus tree, showed the ability to decrease inflammation and improve both obesity and glucose regulation in the test subjects .

"This study goes beyond merely alleviating symptoms. It identifies the accumulation of senescent cells as a key cause not only of aging but also of obesity and metabolic diseases, and proposes a new therapeutic approach that directly eliminates these cells. We expect this to significantly contribute to the treatment of diseases such as obesity and diabetes," explained Professor Park So-young.

Professor Park So-young, Director of the Senotherapy-Based Metabolic Disease Control Research Center, Yeungnam University

The findings were published in Nature Communications, one of the world's most prestigious scientific journals, in March 2026 .

Why Is This Different From Other Anti-Aging Approaches?

The shift in aging research is moving away from simply extending how long we live toward extending "healthy lifespan," the period of life free from disease or disability. Age-related conditions such as obesity, diabetes, and chronic inflammatory diseases are now recognized as major factors that increase healthcare costs and diminish quality of life. This study is particularly significant because it targets one of the fundamental causes of the aging process itself, rather than treating individual diseases in isolation .

Additionally, the research highlights the importance of drug repositioning, a strategy where existing medications are repurposed for new uses. Since homoharringtonine is already clinically approved for treating blood cancer, this approach could dramatically reduce development time and costs while increasing the likelihood of successful commercialization compared to developing entirely new drugs .

What Are the Next Steps for This Research?

The research team has outlined several important directions for future investigation:

• Muscle Aging: The team plans to expand their investigation to sarcopenia, a major age-related condition characterized by loss of muscle mass and strength that significantly impacts quality of life in older adults.
• HSPA5 Protein Regulation: Researchers have identified that homoharringtonine inhibits HSPA5, a critical regulator of protein homeostasis within cells that is closely associated with aging and cellular stress response.
• Next-Generation Treatments: The team is developing inhibitors targeting HSPA5 to create safer and more effective anti-aging treatments that can selectively control senescent cells with greater precision.

"We have also identified a key clue that homoharringtonine inhibits HSPA5, a critical regulator of protein homeostasis within cells. If we can precisely regulate HSPA5, it may enable a new therapeutic strategy to selectively control senescent cells," the research team stated.

Research Team, Senotherapy-Based Metabolic Disease Control Research Center, Yeungnam University

What Could This Mean for the Future of Aging?

The global market for anti-aging therapeutics is rapidly expanding, and treatment strategies that directly target aging mechanisms are emerging as a key sector in the next-generation biotechnology industry. This research suggests that the future of aging treatment may not involve separate drugs for obesity, diabetes, and other age-related conditions, but rather unified approaches that address the cellular damage underlying multiple diseases .

The research was supported by the National Research Foundation of Korea, Gyeongsangbuk-do Province, and Daegu Metropolitan City, and conducted in collaboration with the University of Toronto and The Hospital for Sick Children in Canada . As the world's population ages, findings like these offer hope that we may eventually move beyond simply managing the symptoms of aging toward actually slowing or reversing some of its underlying mechanisms.